Merck's Q2 Earnings Preview: Analysts Forecast $2.04 EPS

Merck & Co., Inc. (MRK) is a healthcare giant with a market cap of $204.3 billion, known for Keytruda. Analysts predict Q2 2025 adjusted EPS at $2.04, down from $2.28 last year. Fiscal 2025 EPS is estimated at $8.91, up 16.5% from 2024. MRK shares fell 34.1% in the past year but rose 1.4% after strong Q1 results. The company reaffirmed its 2025 revenue guidance at $64.1 billion – $65.6 billion. Analysts rate MRK as a “Moderate Buy,” with a current price below the average target of $103.68.

Read more at Yahoo Finance: What You Need To Know Ahead of Merck’s Earnings Release